|Bid||87.28 x 900|
|Ask||87.80 x 1100|
|Day's range||86.85 - 87.79|
|52-week range||74.09 - 94.26|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||9.04|
|Forward dividend & yield||3.33 (3.79%)|
|Ex-dividend date||08 Mar 2022|
|1y target est||100.75|
Novartis (VTX:NOVN) has had a great run on the share market with its stock up by a significant 5.6% over the last...
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and serious complement-mediated blood disorder New data evaluating the superiority of first-line (1L) Kisqali® plus endocrine therapy vs. combination chemotherapy in pre-menopausal patients with HR+/HER2- metastatic breast cancer with aggressive disease, including patients with visceral disease New analysis fr